|23.34||+0.21 / +0.91%|
As of 3:59pm ET
|22.94||-0.40 / -1.71%|
The 8 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 25.50, with a high estimate of 31.00 and a low estimate of 7.00. The median estimate represents a +9.25% increase from the last price of 23.34.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.